Pacira | PCRX - Equity Capital And Reserves


Pacira reported $727.21M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Assertio Holdings USD 105.8M 12.5M Sep/2025
Astellas Pharma JPY 1.76T 150.69B Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Cara Therapeutics USD 32.93M 41M Jun/2025
Coherus Biosciences USD 87.77M 32.05M Sep/2025
Heron Therapeutics USD 14.88M 42.14M Sep/2025
Ironwood Pharmaceuticals USD -264.16M 44M Sep/2025
J&J USD 78.47B 0 Sep/2025
Ligand Pharmaceuticals USD 950.17M 121.64M Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Novo Nordisk DKK 194.05B 24.15B Dec/2025
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 727.21M 30.55M Sep/2025
Perrigo USD 4.45B 25.8M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Supernus Pharmaceuticals USD 1.06B 12.05M Dec/2025
Teva Pharmaceutical Industries USD 7.91B 664M Dec/2025
Xeris Pharmaceuticals USD -861K 18.44M Sep/2025
Xoma USD 87.94M 15.5M Sep/2025
Zoetis USD 3.33B 2.07B Dec/2025